Prostaglandin analogues for eyelash hypotrichosis: an integrated review of mechanisms, clinical trials and cosmetic-use controversies

Background Eyelashes are specialized terminal hairs with key protective and psychosocial roles. Prostaglandin F2α analogues, initially developed as ocular hypotensive agents, were observed to induce eyelash hypertrichosis, leading to their repurposing for the treatment of eyelash hypotrichosis and subsequent incorporation into prescription and over-the-counter (OTC) cosmetic serums. Objectives To provide a narrative, clinically oriented synthesis of (i) the mechanisms by which prostaglandin analogues promote eyelash growth; (ii) evidence for their efficacy and safety in idiopathic and secondary eyelash hypotrichosis; and (iii) periocular adverse effects, particularly prostaglandin-associated periorbitopathy (PAP), in the context of both prescription and cosmetic use. Methods A structured, non-systematic search of PubMed/MEDLINE, Embase and Web of Science (inception to 18 December 2025) was performed, supplemented by manual reference screening and targeted searches for regulatory and professional-society documents. Human studies of prostaglandin analogues reporting eyelash or periocular outcomes, and key mechanistic, ex vivo and regulatory sources, were narratively synthesized. Clinical studies were categorized by study design, and randomized, observational, mechanistic and regulatory evidence are reported separately. Results Randomized trials, mostly short-term and manufacturer-sponsored, show that once-daily bimatoprost 0.03% applied to the upper eyelid margin increases eyelash prominence, length, thickness and darkness in idiopathic and post-chemotherapy hypotrichosis, with limited pediatric data and mainly mild local adverse events. Evidence for latanoprost and other analogues is sparse and inconsistent. Ex vivo and in vitro data implicate the FP receptor in both anagen prolongation and inhibition of adipogenesis. Observational glaucoma data link prostaglandin exposure to PAP, with the highest risk for bimatoprost and partial reversibility, but these data cannot be transferred directly to eyelash or cosmetic use. Switching from FP agonists to the receptor-selective EP2 agonist omidenepag has been shown to reverse deepening of the upper eyelid sulcus (DUES) and lash hypertrichosis, with the latter being the least reversible sign, so the two effects could be separable. Regulatory bodies have raised safety concerns about prostaglandin-containing OTC serums. Conclusions Bimatoprost 0.03% is an effective pharmacologic enhancer of eyelash growth, but prostaglandin analogues carry a recognizable spectrum of periocular adverse effects, and long-term and cosmetic-use safety data remain limited. Careful patient selection, precise application, counselling and, where appropriate, involvement of eye-care professionals are advisable; unsupervised use of prostaglandin-containing OTC serums is not currently supported by adequate evidence.

Authors

Institutions

Publication Details

Journal
Frontiers in Ophthalmology
Published
2026-11-19
DOI
https://doi.org/10.3389/fopht.2026.1988915
Primary Topic
Hair Growth and Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prostaglandin analogues for eyelash hypotrichosis: an integrated review of mechanisms, clinical trials and cosmetic-use controversies

Almuntsrbellah M. Almudimeegh, Khalid Nabil Nagshabandi, Lamar Nabil Nagshabandi
Frontiers in Ophthalmology
Hair Growth and Disorders
article

Prostaglandin analogues for eyelash hypotrichosis: an integrated review of mechanisms, clinical trials and cosmetic-use controversies

Almuntsrbellah M. Almudimeegh, Khalid Nabil Nagshabandi, Lamar Nabil Nagshabandi
article en

Abstract

Background Eyelashes are specialized terminal hairs with key protective and psychosocial roles. Prostaglandin F2α analogues, initially developed as ocular hypotensive agents, were observed to induce eyelash hypertrichosis, leading to their repurposing for the treatment of eyelash hypotrichosis and subsequent incorporation into prescription and over-the-counter (OTC) cosmetic serums. Objectives To provide a narrative, clinically oriented synthesis of (i) the mechanisms by which prostaglandin analogues promote eyelash growth; (ii) evidence for their efficacy and safety in idiopathic and secondary eyelash hypotrichosis; and (iii) periocular adverse effects, particularly prostaglandin-associated periorbitopathy (PAP), in the context of both prescription and cosmetic use. Methods A structured, non-systematic search of PubMed/MEDLINE, Embase and Web of Science (inception to 18 December 2025) was performed, supplemented by manual reference screening and targeted searches for regulatory and professional-society documents. Human studies of prostaglandin analogues reporting eyelash or periocular outcomes, and key mechanistic, ex vivo and regulatory sources, were narratively synthesized. Clinical studies were categorized by study design, and randomized, observational, mechanistic and regulatory evidence are reported separately. Results Randomized trials, mostly short-term and manufacturer-sponsored, show that once-daily bimatoprost 0.03% applied to the upper eyelid margin increases eyelash prominence, length, thickness and darkness in idiopathic and post-chemotherapy hypotrichosis, with limited pediatric data and mainly mild local adverse events. Evidence for latanoprost and other analogues is sparse and inconsistent. Ex vivo and in vitro data implicate the FP receptor in both anagen prolongation and inhibition of adipogenesis. Observational glaucoma data link prostaglandin exposure to PAP, with the highest risk for bimatoprost and partial reversibility, but these data cannot be transferred directly to eyelash or cosmetic use. Switching from FP agonists to the receptor-selective EP2 agonist omidenepag has been shown to reverse deepening of the upper eyelid sulcus (DUES) and lash hypertrichosis, with the latter being the least reversible sign, so the two effects could be separable. Regulatory bodies have raised safety concerns about prostaglandin-containing OTC serums. Conclusions Bimatoprost 0.03% is an effective pharmacologic enhancer of eyelash growth, but prostaglandin analogues carry a recognizable spectrum of periocular adverse effects, and long-term and cosmetic-use safety data remain limited. Careful patient selection, precise application, counselling and, where appropriate, involvement of eye-care professionals are advisable; unsupervised use of prostaglandin-containing OTC serums is not currently supported by adequate evidence.

Frontiers in OphthalmologyVol. 6
Alfaisal University (SA), King Saud University (SA)
Hair Growth and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon